Role of PET and SPECT in the study of amyotrophic lateral sclerosis.
Angelina CistaroVincenzo CuccurulloNatale QuartuccioMarco PaganiMaria Consuelo ValentiniLuigi MansiPublished in: BioMed research international (2014)
Amyotrophic lateral sclerosis has been defined as a "heterogeneous group of neurodegenerative syndromes characterized by progressive muscle paralysis caused by the degeneration of motor neurons allocated in primary motor cortex, brainstem, and spinal cord." A comprehensive diagnostic workup for ALS usually includes several electrodiagnostic, clinical laboratory and genetic tests. Neuroimaging exams, such as computed tomography, magnetic resonance imaging and spinal cord myelogram, may also be required. Nuclear medicine, with PET and SPECT, may also play a role in the evaluation of patients with ALS, and provide additional information to the clinicians. This paper aims to offer to the reader a comprehensive review of the different radiotracers for the assessment of the metabolism of glucose (FDG), the measurement of cerebral blood flow (CBF), or the evaluation of neurotransmitters, astrocytes, and microglia by means of newer and not yet clinically diffuse radiopharmaceuticals.
Keyphrases
- amyotrophic lateral sclerosis
- spinal cord
- pet ct
- computed tomography
- positron emission tomography
- magnetic resonance imaging
- neuropathic pain
- cerebral blood flow
- spinal cord injury
- pet imaging
- multiple sclerosis
- contrast enhanced
- inflammatory response
- skeletal muscle
- low grade
- healthcare
- palliative care
- high grade
- image quality
- blood pressure
- insulin resistance